Management of Autoimmune Encephalitis in the Neurocritical Care Unit

doi:10.1017/9781107587908.018

Chapter 18 - Management of Autoimmune Encephalitis in the Neurocritical Care Unit

Published online by Cambridge University Press: 24 July 2019

Murat Sari ,

Diana Greene-Chandos and

Michel T. Torbey

Edited by

Michel T. Torbey

Show author details

Michel T. Torbey: Affiliation:
Ohio State University

Book contents

Get access

Summary

Antibody-associated disorders of the central nervous system (CNS) are divided into two broad categories: classic paraneoplastic disorders and autoimmune disorders (i.e. autoimmune encephalitis) [1]. Autoimmune encephalitis is associated with antibodies that bind to cell surface determinants of membrane-associated proteins on neuronal cells (neuronal surface antibody syndrome –NSAb), whereas paraneoplastic syndromes are associated with intracellular neuronal antigens. It can be challenging at times to differentiate between the two syndromes. Patients with NSAb usually present with an acute or subacute symptom onset, with short duration to nadir, and a very good response to immunotherapy [2]. Table 18.1 summarizes some of the characteristics of each. In this chapter, we will focus on the diagnosis and management of autoimmune encephalitis (AE).

Type: Chapter
Information: Neurocritical Care , pp. 233 - 237

DOI: https://doi.org/10.1017/9781107587908.018 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2019

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Book purchase

Temporarily unavailable

References

Dalmau, J, Rosenfeld, MR. (2014). Autoimmune encephalitis update. Neuro Oncol, 16(6): 771–778.Google Scholar

Zuliani, L, Graus, F, Giometto, B, Bien, C, Vincent, A. (2012). Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry, 83(6): 638–645.Google Scholar

Graus, F, Keime-Guibert, F, Reñe, R, et al. (2001). Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain, 124(Pt 6): 1138–1148.Google Scholar

Gable, MS, Sheriff, H, Dalmau, J, Tilley, DH, Glaser, CA. (2012). The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis, 54(7): 899–904.Google Scholar

Armangue, T, Titulaer, MJ, Málaga, I, et al. (2013). Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr, 162(4): 850–856.Google Scholar

De Bruijn, MA, Titulaer, MJ. (2016). Anti-NMDAR encephalitis and other glutamate and GABA receptor antibody encephalopathies. Handb Clin Neurol, 133: 199–217.Google Scholar

Titulaer, MJ, McCracken, L, Gabilondo, I, et al. (2013). Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol, 12(2): 157–165.Google Scholar

Dalmau, J, Gleichman, AJ, Hughes, EG, et al. (2008). Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol, 7(12): 1091–1098.Google Scholar

Gresa-Arribas, N, Titulaer, MJ, Torrents, A, et al. (2014). Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol, 13(2): 167–177.Google Scholar

Schmitt, SE, García-Ptacek, S, García-García, ME, et al. (2012). Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology, 79(11): 1094–1100.Google Scholar

Florance, NR, Davis, RL, Lam, C, et al., (2009). Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol, 66(1): 11–18.CrossRef Google Scholar PubMed

Lai, M, Hughes, EG, Peng, X, et al. (2009). AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol, 65(4): 424–434.Google Scholar

Spatola, M, Petit-Pedrol, M, Simabukuro, MM, et al. (2017). Investigations in GABAA receptor antibody-associated encephalitis. Neurology, 88(11): 1012–1020.Google Scholar

Lancaster, E. (2017). Paraneoplastic disorders. Continuum (Minneap Minn), 23(6 Neuro-oncology): 1653–1679.Google Scholar

Lancaster, E, Lai, M, Peng, X, et al. (2010). Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol, 9(1): 67–76.CrossRef Google Scholar

Ohkawa, T, Fukata, Y, Yamasaki, M, et al. (2013). Autoantibodies to epilepsy-related LGI1 in limbic encephalitis neutralize LGI1-ADAM22 interaction and reduce synaptic AMPA receptors. J Neurosci, 33(46): 18,161–18,174.Google Scholar

van Sonderen, A, Thijs, RD, Coenders, EC, et al. (2016). Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology, 87(14): 1449–1456.Google Scholar

Armangue, T, Leypoldt, F, Málaga, I, et al. (2014). Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol, 75(2): 317–323.Google Scholar

Armangue, T, Leypoldt, F, Dalmau, J. (2014). Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Curr Opin Neurol, 27(3): 361–368.Google Scholar

Titulaer, MJ, Soffietti, R, Dalmau, J, et al. (2011). Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol, 18(1): 19–e3.Google Scholar

Harutyunyan, G, Hauer, L, Dünser, MW, et al. (2017). Autoimmune encephalitis at the neurological intensive care unit: etiologies, reasons for admission and survival. Neurocrit Care, 27(1): 82–89.CrossRef Google Scholar PubMed

Clowse, ME, Behera, MA, Anders, CK, et al. (2009). Ovarian preservation by GnRH agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt), 18(3): 311–319.Google Scholar